osteoarthritis

Genzyme Announces Results of Clinical Trial of Hylastan

...icacy of hylastan in treating painin patients with osteoarthritis (OA) of the knee. Hylastan is beingdeveloped withi...ve-controlstudy involving nearly 400 patients with osteoarthritis of the kneeenrolled at 27 sites in North America and Europe. Patients wererandomized to receive two ...

Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee

...(formerly 4975) in patients withmoderate-to-severe osteoarthritis of the knee produced substantialreductions in pain...l prove to be a safeand effective drug in multiple osteoarthritis indications," saidJohn P. McLaughlin, chief executive officer of Anesiva. "We areon-track to advance...

Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension

...surecompared to ibuprofen[1] * Many patients with osteoarthritis also have high bloodpressure; even small changes i...untries and currently underreview in US for use in osteoarthritis patients BASEL, Switzerland, June 15, 2007 - Patients with osteoarthritiswho also have controlled h...

Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension

..., are importantbecause around 40% of patients with osteoarthritis also have highblood pressure (or hypertension). W...The new researchunderlines how important it is for osteoarthritis patients to havea treatment option such as lumiracoxib." The study presented at EULAR was a four-we...

Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR

...nically meaningfulbenefits of CRx-102 treatment in osteoarthritis (OA) from anindividual patient perspective were evaluated. CRx-102 consistentlyshowed clinically meaningful benefit across these outcome measuresand responder analyses: -- BLISS response of individual pain of less than or equal to 20(27% CRx-102 v...

Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting

...phase 2 clinical trials ofCRx-102 in patients with osteoarthritis (OA) and rheumatoidarthritis (RA) will be featured at the European League againstRheumatism (EULAR) Annual Congress of Rheumatology meeting, June13-16, 2007 in Barcelona, Spain. Schedule of Events: -- Satellite Symposium, Room 111, Thursday, June 14...

First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A) Significantly Improves Idiopathic Detrusor Overactivity (IDO) in Patients With Symptoms of Overactive Bladder

...inary incontinencedaily." OAB is more common than osteoarthritis or diabetes(1,2) and isestimated to affect 16-17% of the population in the U.S. andWestern Europe.(3) In addition, the economic burden of OAB issubstantial. In the U.S., for example, the total economic cost ofOAB has been estimated at $12 billion in ...

Ferring Reports on ENDOMETRIN Presentations at Pacific Coast Reproductive Society Annual Meeting

...ncludesEUFLEXXA(TM), hyaluronic acid for pain from osteoarthritis in theknee. Other products include ACTHREL(R) (corticorelin ovinetriflutate for injection) for the differential diagnosis ofCushing's syndrome and DESMOPRESSIN ACETATE in injectable andrhinal tube forms for the treatment of diabetes insipidus andprim...

CombinatoRx Provides Topline Results from Phase 2 RA Study with CRx-139 and Very Low Dose Prednisolone

...y effect and rapid onset ofaction in patients with osteoarthritis and rheumatoid arthritis, aswell as in a biomarker study, and was generally well tolerated.CRx-102 is being developed in a modified-release commercialformulation for the treatment of multiple immuno-inflammatorydiseases. About CombinatoRx Combinato...

New Phase IV Clinical Study Indicates LidoSite Provides Rheumatology Patients Superior Pain Relief

...have to get injections everysix months to treat my osteoarthritis with the pain often more thanI care to experience, but using LidoSite has been a tremendousbenefit to me and I'm sure to other arthritic patients." The American Pain Society (APS) and the American Academy ofPediatrics (AAP) set forth guidelines for ...

POZEN Announces Positive Outcome for PA 325 Proof of Concept Study

...magnesium in a singletablet for conditions such as osteoarthritis and rheumatoidarthritis in patients who are at risk for developingNSAID-associated gastric ulcers. The company's common stock istraded on The Nasdaq Stock Market under the symbol "POZN". Fordetailed company information, including copies of this and o...

Pozen Announces Positive Outcome for PA 325

...magnesium in a single tablet forconditions such as osteoarthritis and rheumatoid arthritis inpatients who are at risk for developing NSAID-associated gastriculcers. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailedcompany information, including copies of this and...